Table 1.
Osteoporosis medications (other than teriparatide) prior and during the course of the study.
| Medication | Past use at baseline (N = 301) |
Ongoing at baseline (N = 301) |
3 months (N = 297)a |
6 months (N = 282)a |
12 months (N = 280)a |
18 months (N = 278)a |
|---|---|---|---|---|---|---|
| Any medication | 83.7% | 74.0% | 78.6% | 79.0% | 81.4% | 76.9% |
| Any antiresorptives | 81.7% | 34.4% | 6.8% | 7.1% | 7.9% | 9.4% |
| Any bisphosphonates | 38.0% | 12.0% | 0.7% | 0.7% | 1.8% | 2.5% |
| Estrogen/progestin therapy | 1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Estrogen therapy | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Raloxifene | 7.0% | 1.0% | 1.0% | 0.7% | 0.4% | 0.4% |
| Calcitonin | 65.0% | 21.4% | 6.1% | 6.0% | 5.7% | 6.5% |
| Calcium | 68.0% | 67.7% | 75.6% | 78.6% | 81.1% | 75.5% |
| Vitamin D | 53.7% | 62.5% | 72.2% | 74.0% | 75.0% | 70.8% |
| None reported | 16.3% | 26.0% | 21.4% | 21.0% | 18.6% | 23.1% |
aStarted since previous observation.